Results 11 to 20 of about 75,323 (218)

CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

BMC Immunology, 2020
Background Early detection of capecitabine-resistance could largely increase overall survival of colorectal cancer (CRC) patients. Previous studies suggested examination of immune cells in peripheral blood would help to predict efficacy of chemotherapy ...
Yu Lu, Yizhou Huang, Lei Huang, Yanjie Xu, Zien Wang, Han Li, Ting Zhang, Ming Zhong, Wei-qiang Gao, Yan Zhang   +9 more
doaj   +1 more source

Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [PDF]

, 2013
The potential clinical utility of genetic markers associated with response to fluoropyrimidine treatment in colorectal cancer patients remains controversial despite extensive study.
A Fariña-Sarasqueta, A Loganayagam, A Ruzzo, A Ruzzo, A Yawata, A Zaniboni, Andreas-Claudius Hoffmann, Ann Barrett, B Glimelius, BA Jennings, Barbara A. Jennings, C Fernandez-Rozadilla, C Zhang, CE de Bock, CF Thorn, D Caronia, Daniel Epurescu, DB Longley, E Hitre, E Van Cutsem, G Willis, Gavin S. Chu, Gavin Willis, H Gellekink, H Taflin, I Weisberg, J Cassidy, Jane Skinner, K Derwinger, K Kawakami, K Kawakami, L Peter, L Sharp, M Boisdron-Celle, M Gusella, M Scartozzi, M Schwab, M Vignoli, ME Fernández-Contreras, Melanie Keane, MJ Deenen, MS Braun, MV Mandola, MV Mandola, MV Mandola, N Horie, P Frosst, R Pullmann Jr., RA Goodwin, Richard Turner, S Afzal, S Afzal, S Kaneda, T André, TV Perneger, V Sulzyc-Bielicka, W Ichikawa, W Scheithauer, WG Johnson, Yoon K. Loke   +59 more
core   +8 more sources

Visfatin and Resveratrol Differentially Regulate the Expression of Thymidylate Synthase to Control the Sensitivity of Human Colorectal Cancer Cells to Capecitabine Cytotoxicity

Life, 2021
Colorectal cancer (CRC) is a highly lethal malignant cancer. Capecitabine, a 5-fluororacil (5-FU) derivate, is its first-line drug, but the resistance of CRC to capecitabine is still the most challenging factor for curing patients.
Kuen-Lin Wu, Ko-Chao Lee, Chia-Kuang Yen, Cheng-Nan Chen, Shun-Fu Chang, Wen-Shih Huang   +5 more
doaj   +1 more source

Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients

Saudi Pharmaceutical Journal, 2022
Background: Capecitabine is one of the fluoropyrimidine anticancer agents which is extensively used in the management of colorectal cancer. We have noticed a discrepancy between the doses we are using in our patients and the recommended dosing regimen ...
Saeed Alqahtani, Rawan Alzaidi, Abdullah Alsultan, Abdulaziz Asiri, Yousif Asiri, Khalid Alsaleh   +5 more
doaj   +1 more source

Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases

Cancer Communications, 2018
Background Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (
Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajovà, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo, Maria Aurelia Barbera   +11 more
doaj   +1 more source

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]

, 2013
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Arnold, Dirk, Dellas, Kathrin, Dunst, Jürgen, Engel, Erik, Höhler, Thomas, Reese, Thomas, Richter, Michael, Rödel, Claus, Wagner, Wolfgang, Würschmidt, Florian   +9 more
core   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

Capecitabine-Associated Terminal Ileitis

Case Reports in Oncology, 2018
Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents.
Irene E.G. van Hellemond, Annemarie M. Thijs, Geert-Jan Creemers   +2 more
doaj   +1 more source

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis, F. Y. Coxon, J. S. Graham, K. Boyd, L. R. Wall, M. Highley, M. M. Eatock, P. Bützberger-Zimmerli, S. Harden, T. R. J. Evans, T. S. Maughan   +10 more
core   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source